Cytomegalovirus protease targeted prodrug development

Molecular Pharmaceutics

Volumn 10, Issue 4, 2013, Pages 1417-1424

  Sabit, Hairat ^a   Dahan, Arik ^b   Sun, Jing ^a   Provoda, Chester J ^a   Lee, Kyung Dall ^a   Hilfinger, John H ^c   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c TSRL INC   (United States)

Author keywords

drug delivery; ganciclovir; human cytomegalovirus protease; prodrug; prodrug activation; prodrug targeting; site specific

Indexed keywords

AC ALANINE GANCICLOVIR; ALANINE GANCICLOVIR MONO ESTER; BOC ALANINE GANCICLOVIR; BZ ALANINE GANCICLOVIR MONO ESTER; CBZ ALANINE GANCICLOVIR; ESTERASE; GANCICLOVIR; PRODRUG; PROTEINASE; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN CACO 2; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HYDROLYSIS; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS CAPSID;

ANIMALS; ANTIVIRAL AGENTS; CACO-2 CELLS; CLONING, MOLECULAR; CYTOMEGALOVIRUS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ESTERS; GANCICLOVIR; HUMANS; HYDROLYSIS; KINETICS; MICROSOMES, LIVER; MODELS, CHEMICAL; MUTATION; PEPTIDE HYDROLASES; PRODRUGS; RATS; TEMPERATURE;

EID: 84875782555     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3007067     Document Type: Article

References (22)

1. Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs J. Med. Chem. 2004, 47 (10) 2393-404
2. Dahan, A.; Khamis, M.; Agbaria, R.; Karaman, R. Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach Expert Opin. Drug Delivery 2102, 9 (8) 1001-13
3. Han, H. K.; Amidon, G. L. Targeted prodrug design to optimize drug delivery AAPS PharmSci 2000, 2 (1) E6
4. Weller, T. H. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I N. Engl. J. Med. 1971, 285 (4) 203-14
5. Fields, B. N.; Knipe, D. M.; Howley, P. M., Eds. Fields Virology 3 rd ed.; Lippincott-Raven Publishers: 1996
6. Montgomery, J. A. Purine nucleoside phosphorylase: a target for drug design Med. Res. Rev. 1993, 13 (3) 209-28
7. Martin, J. C.; Dvorak, C. A.; Smee, D. F.; Matthews, T. R.; Verheyden, J. P. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent J. Med. Chem. 1983, 26 (5) 759-61
8. Cvetkovic, R. S.; Wellington, K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients Drugs 2005, 65 (6) 859-78
9. Sinclair, J.; Sissons, P. Latency and reactivation of human cytomegalovirus J. Gen. Virol. 2006, 87 (Part 7) 1763-79
10. Sia, I. G.; Wilson, J. A.; Groettum, C. M.; Espy, M. J.; Smith, T. F.; Paya, C. V. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation J. Infect. Dis. 2000, 181 (2) 717-20
11. Lalezari, J.; Lindley, J.; Walmsley, S.; Kuppermann, B.; Fisher, M.; Friedberg, D.; Lalonde, R.; Matheron, S.; Nieto, L.; Torriani, F. J.; Van Syoc, R.; Sutton, M. A.; Buhles, W.; Stempien, M. J. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis J. Acquired Immune Defic. Syndr. 2002, 30 (4) 392-400
12. Matusick-Kumar, L.; Newcomb, W. W.; Brown, J. C.; McCann, P. J., 3rd; Hurlburt, W.; Weinheimer, S. P.; Gao, M. The C-terminal 25 amino acids of the protease and its substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsids J. Virol. 1995, 69 (7) 4347-56
13. Welch, A. R.; Woods, A. S.; McNally, L. M.; Cotter, R. J.; Gibson, W. A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site Proc. Natl. Acad. Sci. U.S.A. 1991, 88 (23) 10792-6
14. Baum, E. Z.; Bebernitz, G. A.; Hulmes, J. D.; Muzithras, V. P.; Jones, T. R.; Gluzman, Y. Expression and analysis of the human cytomegalovirus UL80-encoded protease: identification of autoproteolytic sites J. Virol. 1993, 67 (1) 497-506
15. Darke, P. L.; Cole, J. L.; Waxman, L.; Hall, D. L.; Sardana, M. K.; Kuo, L. C. Active human cytomegalovirus protease is a dimer J. Biol. Chem. 1996, 271 (13) 7445-9
16. Qiu, X.; Culp, J. S.; DiLella, A. G.; Hellmig, B.; Hoog, S. S.; Janson, C. A.; Smith, W. W.; Abdel-Meguid, S. S. Unique fold and active site in cytomegalovirus protease Nature 1996, 383 (6597) 275-9
17. Chen, P.; Tsuge, H.; Almassy, R. J.; Gribskov, C. L.; Katoh, S.; Vanderpool, D. L.; Margosiak, S. A.; Pinko, C.; Matthews, D. A.; Kan, C. C. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad Cell 1996, 86 (5) 835-43
18. Liu, F. Y.; Kildsig, D. O.; Mitra, A. K. Cyclodextrin/weak-electrolyte complexation: interpretation and estimation of association constants from phase solubility diagrams Pharm. Res. 1992, 9 (12) 1671-2
19. LaPlante, S. R.; Aubry, N.; Bonneau, P. R.; Cameron, D. R.; Lagace, L.; Massariol, M. J.; Montpetit, H.; Plouffe, C.; Kawai, S. H.; Fulton, B. D.; Chen, Z.; Ni, F. Human cytomegalovirus protease complexes its substrate recognition sequences in an extended peptide conformation Biochemistry 1998, 37 (27) 9793-801
20. Bonneau, P. R.; Plouffe, C.; Pelletier, A.; Wernic, D.; Poupart, M. A. Design of fluorogenic peptide substrates for human cytomegalovirus protease based on structure-activity relationship studies Anal. Biochem. 1998, 255 (1) 59-65
21. O'Boyle, D. R., 2nd; Wager-Smith, K.; Stevens, J. T., 3rd; Weinheimer, S. P. The effect of internal autocleavage on kinetic properties of the human cytomegalovirus protease catalytic domain J. Biol. Chem. 1995, 270 (9) 4753-8
22. LaFemina, R. L.; Bakshi, K.; Long, W. J.; Pramanik, B.; Veloski, C. A.; Wolanski, B. S.; Marcy, A. I.; Hazuda, D. J. Characterization of a soluble stable human cytomegalovirus protease and inhibition by M-site peptide mimics J. Virol. 1996, 70 (7) 4819-24